SCHEMBL20468960

SCHEMBL20468960

Cc1cncc(N2CCC3(CCN(C(=O)OC(C)(C)C)C3)C2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.56
▸ ACACB O00763 5/20 0.50
▸ SCD5 Q86SK9 1/20 0.47
▸ CYP3A4 P08684 4/20 0.46
▸ CYP2C9 P11712 3/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ CYP1A2 P05177 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ HDAC2 Q92769 2/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ RET P07949 1/20 0.42
▸ GPR183 P32249 1/20 0.41
▸ GPR119 Q8TDV5 2/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ TNKS O95271 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ TNKS2 Q9H2K2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13015290 0.87 EGLN2 (0.47) CYP11B2ACACBRETGPR119PARP1
SCHEMBL20468959 0.87 CYP11B2 (0.57) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20468939 0.86 CYP11B2 (0.57) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20468961 0.86 CYP11B2 (0.53) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20468945 0.83 ACACB (0.52) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20468940 0.83 CYP11B2 (0.53) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20469135 0.83 CYP11B2 (0.53) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL21711129 0.83 CYP11B2 (0.53) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20469072 0.83 CYP11B2 (0.59) CYP11B2ACACBSCD5CYP3A4CYP2C9
SCHEMBL20842160 0.82 GPR119 (0.57) CYP11B2ACACBSCD5CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048267-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2020-02-13 — — US disclosed
WO-2018141984-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048267-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN CYP11B2 4635/4885ACACB 639/4885SCD5 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback